Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED is steadily executing on its strategy to accelerate its path to sustainable profitability from FY25. This remains centred around commercial delivery and near-term value creation from the most advanced in-house pipeline assets as the company transitions from a China-based R&D-focused biopharma to a fully integrated commercial enterprise addressing the significant global market opportunity with its Oncology/Immunology products. Commercial traction in China is building for first wave products, partner Takeda has launched the first HUTCHMED product in the US, and key pipeline programmes are progressing with multiple near-term clinical and regulatory catalysts for new indications, new markets, and new products. In our view, HUTCHMED represents a unique biopharma opportunity with a broad pipeline of largely de-risked late-stage assets, global ambitions supported by large pharma partners, proven commercial execution in China yielding a growing top line, all balanced with shrewd investment. Our HUTCHMED valuation is $6.10bn/£5.09bn/HK$47.61bn, or $35.03/ADS and 584p/HK$54.64 per share.

Market information



R&D day highlights prospects for key late-stage products
Lighthouse | 11 Jul 2024
Data at EHA 2024 heighten focus on sovleplenib
Update | 25 Jun 2024
Strong US Fruzaqla Q1; EU approval could come soon
Lighthouse | 13 May 2024

Recent News

Tazemetostat China NDA acceptance with Priority Review for r/r FL
04 Jul 2024
Save the Date: R&D Updates on July 9, 2024
24 Jun 2024
European Commission approval for FRUZAQLA (fruquintinib) received by Takeda
22 Jun 2024
Publication of Phase III ESLIM-01 results in The Lancet Haematology
17 Jun 2024